Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy

Science

Volumn 307, Issue 5706, 2005, Pages 58-62

  Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD VESSELS; DRUG PRODUCTS; MEDICINE; MOLECULAR BIOLOGY; NUTRITION; TUMORS;

ANTIANGIOGENIC THERAPIES; TUMOR VASCULATURE; VASCULAR NORMALIZATION;

DISEASES;

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 1; ANTIINFECTIVE AGENT; BEVACIZUMAB; CETUXIMAB; ENDOSTATIN; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; GEFITINIB; IMATINIB; MATRIX METALLOPROTEINASE; PLACENTAL GROWTH FACTOR; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2; VATALANIB;

MEDICINE;

ANGIOGENESIS; ARTERY THROMBOSIS; BLOOD VESSEL FUNCTION; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; ENDOCRINE DISEASE; ENDOTHELIUM CELL; HUMAN; HYPERTENSION; HYPOXIA; NEUROLOGIC DISEASE; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SOLID TUMOR; TUMOR BLOOD FLOW; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VASCULARIZATION; VASCULAR DISEASE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL HYPOXIA; CELL PROLIFERATION; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 11844254414     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1104819     Document Type: Review

References (60)

1. J. Folkman, N. Engl. J. Med. 285, 1182 (1971).
2. J. C. Yang et al., N. Engl. J. Med. 349, 427 (2003).
3. M. A. Cobleigh et al., Semin. Oncol. 30, 117 (2003).
4. R. J. Mayer, N. Engl. J. Med. 350, 2406 (2004).
5. H. Hurwitz et al., N. Engl. J. Med. 350, 2335 (2004).
6. B. A. Teicher, Cancer Metastasis Rev. 15, 247 (1996).
7. D. J. Hicklin, L. M. Ellis, J. Clin. Oncol., in press.
8. J. Ma et al., Cancer Res. 61, 5491 (2001).
9. R. Murata, Y. Nishimura, M. Hiraoka, Int. J. Radiat. Oncol. Biol. Phys. 37, 1107 (1997).
10. B. M. Fenton, S. F. Paoni, I. Ding, Radiother. Oncol. 72, 221 (2004).
11. R. K. Jain, Nature Med. 7, 987 (2001).
12. P. Carmeliet, R. K. Jain, Nature 407, 249 (2000).
13. R. K. Jain, in Clinical Oncology, M. Abeloff et al., Eds. (Elsevier, New York. ed. 3, 2004), pp. 153-172.
14. T. P. Padera et al., Nature 427, 695 (2004).
15. D. P. Bottaro, L. A. Liotta, Nature 423, 593 (2003).
16. S. K. Hobbs et al., Proc. Natl. Acad. Sci. U.S.A. 95, 4607 (1998).
17. R. K. Jain, Clin. Cancer Res. 5, 1605 (1999).
18. R. K. Jain, Nature Med. 9, 685 (2003).
19. M. Ratner, Nature Biotechnol. 22, 1198 (2004).
20. H. F. Dvorak, J. Clin. Oncol. 20, 4368 (2002).
21. N. Ferrara, K. J. Hillan, H. P. Gerber, W. Novotny, Nature Rev. Drug Discov. 3, 391 (2004).
22. J. A. Nagy et al., J. Exp. Med. 196, 1497 (2002).
23. C. G. Lee et al., Cancer Res. 60, 5565 (2000).
24. R. T. Tong et al., Cancer Res. 64, 3731 (2004).
25. F. Yuan et al., Proc. Natl. Acad. Sci. U.S.A. 93, 14765 (1996).
26. A. Kadambi et al., Cancer Res. 61, 2404 (2001).
27. T. Inai et al., Am. J. Pathol. 165, 35 (2004).
28. H. Wildiers et al., Br. J. Cancer 88, 1979 (2003).
29. F. Winkler et al., Cancer Cell 6, 553 (2004).
30. Y. Gazit et al., Microcirculation 4, 395 (1997).
31. C. G. Willett et al., Nature Med. 10, 145 (2004).
32. B. Morgan et al., J. Clin. Oncol. 21, 3955 (2003).
33. H. Q. Xiong et al., Invest. New Drugs 22, 459 (2004).
34. R. S. Herbst et al., J. Clin. Oncol. 20, 3804 (2002).
35. F. Baffert et al., Circ. Res. 94, 984 (2004).
36. M. Relf et al., Cancer Res. 57, 963 (1997).
37. Y. Izumi, L. Xu, E. di Tomaso, D. Fukumura, R. K. Jain, Nature 416, 279 (2002).
38. B. Goldman, J. Natl. Cancer Inst. 95, 1744 (2003).
39. P. Perrotte et al., Clin. Cancer Res. 5, 257 (1999).
40. S. J. Kim et al., Cancer Res. 64, 4201 (2004).
41. R. Kerbel, J. Folkman, Nature Rev. Cancer 2, 727 (2002).
42. B. Vogelstein, K. W. Kinzler, Nature Med. 10, 789 (2004).
43. D. Hanahan, R. A. Weinberg, Cell 100, 57 (2000).
44. P. M. Gullino, in Biomedical Thermology, M. Gautherie, E. Albert, Eds. (A. R. Liss, New York, 1982), pp. 1-20.
45. L. Flintoft, Nature Rev. Cancer 4, 754 (2004).
46. D. A. Nelson et al., Genes Dev. 18, 2095 (2004).
47. R. K. Jain et al., Proc. Natl. Acad. Sci. U.S.A. 95, 10820 (1998).
48. R. S. Kerbel, B. A. Kamen, Nature Rev. Cancer 4, 423 (2004).
49. K. Hellmann, Clin. Exp. Metastasis 20, 95 (2003).
50. G. Griffon-Etienne, Y. Boucher, C. Brekken, H. D. Suit, R. K. Jain, Cancer Res. 59, 3776 (1999).
51. D. W. Siemann, D. J. Chaplin, M. R. Horsman, Cancer 100, 2491 (2004).
52. P. E. Thorpe, Clin. Cancer Res. 10, 415 (2004).
53. E. Ruoslahti, Nature Rev. Cancer 2, 83 (2002).
54. Vascular targeting agents (VTAs) and cytotoxic agents presumably target different regions of a tumor. VTAs indirectly kill cancer cells by choking the tumor's btood supply, but leave a viable rim of cancer cells. It is the latter cells that are the target of chemotherapy or radiation therapy. The order in which the tumor and vascular cells are targeted may be key to the success of this approach. The greatest therapeutic benefit may come when blood vessels are destroyed after chemotherapy. In this scenario, the cytotoxic drug will be retained in the tumor for a longer period because there is no longer an efficient means of egress. It is worth noting here that the efficacy of these agents has not yet been proven in the clinic with phase III trials. Even in preclinical studies, the effects of combined VTAs and conventional therapies have been additive at best, whereas the effects of combined antibody to VEGFR2 and fractionated radiation - given during the normalization window - have been synergistic (i.e., more than additive) (29).
55. J. S. Rasey et al., Int. J. Radiat. Oncol. Biol. Phys. 36, 417 (1996).
56. S. Gross, A. Gilead, A. Scherz, M. Neeman, Y. Salomon, Nature Med. 9, 1327 (2003).
57. P. Carmeliet, Nature Med. 9, 653 (2003).
58. FDA, www.thepinksheet.com/nr/FDC/SupportingDocs/pink/2004/ 040830_Macugen_fda_materials.pdf (2004).
59. N. Koike et al., Nature 428, 138 (2004).
60. The author thanks the members of the Steele Lab, especially M. Booth, Y. Boucher, E. diTomaso, D. G. Duda, D. Fukumura, S. Kozin, L. Munn, T. Padera, R. Tong, C. Willett, and F. Winkler; and B. Chabner, H. Chen, L. Ellis, J. Folkman, R. Jones, K. Novak, J. Samson, R. Weinberg, and B. Zetter for their helpful comments on this manuscript. The author is a consultant to AstraZeneca. This work was supported by grants from the National Cancer Institute.